



HHS Public Access

Author manuscript

Cancer Cell. Author manuscript; available in PMC 2020 July 23.

Published in final edited form as:

Cancer Cell. 2020 February 10; 37(2): 258–259. doi:10.1016/j.ccell.2020.01.010.

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in *HER2*-Mutant Cancers

Dhivya R. Sudhan, Angel Guerrero-Zotano, Helen Won, Paula González Ericsson, Alberto Servetto, Mariela Huerta-Rosario, Dan Ye, Kyung-min Lee, Luigi Formisano, Yan Guo, Qi Liu, Lisa N. Kinch, Monica Red Brewer, Teresa Dugger, James Koch, Michael J. Wick, Richard E. Cutler Jr., Alshad S. Lalani, Richard Bryce, Alan Auerbach, Ariella B. Hanker^{*}, Carlos L. Arteaga^{*}

In the originally published version of this article, during final figure preparation the authors inadvertently selected an incorrect dose response graph for Figure 1D (bottom row, middle sub-panel; parental versus neratinib-resistant OVCAR8 lapatinib dose response assay). The lapatinib sensitivity graph for 5637 cells from the top row was mistakenly copied into the OVCAR8 panel. The correction to the graph in Figure 1D does not affect the conclusions of the paper. The authors apologize for any confusion or inconvenience that this oversight may have caused.

^{*}Correspondence: ariella.hanker@utsouthwestern.edu (A.B.H.), carlos.arteaga@utsouthwestern.edu (C.L.A.).




Figure 1.
Generation and Characterization of *HER2*-Mutant Cells with Acquired Resistance to Neratinib (Corrected)




Figure 1.
Generation and Characterization of *HER2*-Mutant Cells with Acquired Resistance to Neratinib (Original)